Vector-borne and Malarial Diseases Research Group


  • In vitro and molecular resistance patterns antimalarial drugs
  • Diagnosis, epidemiology, molecular analysis, pathogenesis and emerging drug resistance of vecto
  • Molecular epidemiology of Plasmodium species,
  • r-borne infections


  • Dr M Asim Beg
  • Dr Erum Khan
  • Dr Najia Ghanchi
  • Dr Afsheen Raza
  • Dr Joveria Farooqi
  • Dr Sadia Shakoor
  • Ms Amna Nasir
  • Dr Akbar Kanji
  • Ms Muniba Islam
  • Dr Ali Bin Sarwar Zubairi


  • London School of Hygiene and Tropical Medicine, UK.
  • Malaria Control Program, Pakistan.
  • Harvard school of Public Health, USA
  • Malaria Branch, Centres for Disease Control (CDC), USA


  • The Role of Arboviruses undifferentiated as a cause of febrile illness in Sindh Pakistan
    Funded by DTRA. $ 116,796. 2014-2017.
  • Identification for severity markers in vivax malaria
    Rs 1,630,055. 2011-2014.
  • Antimalarial resistance in P. falciparum: Role of single nucleotide polymorphism in resistance associated genes and in vitro drug sensitivities.
    USD $15,000. 2012 - 2014 


  • Point-of-Care Technology for the Diagnosis of Multiple Diseases: A Solution to the Disease Overtreatment Problem.
    100,000 CAD. Funded by Canadian Grand Challenges. 2012.
    Dr Michael Serpe (University of Alberta)
  • Molecular basis of glucose-6-phoshate dehydrogenase deficiency in the Afghan population
    $10,000. Funded by Health Net, London School of Hygiene and Tropical Medicine. 2011.
  • Emerging infectious agents mimicking functional bowel disease.
    Rs. 1 million Funded by the Government of Pakistan Higher Education Commission. 2008- 2010.
  • P.vivax malaria: Population genetics and markers of drug resistance in an endemic region.
    WHO $ 9,000. 2008-2009.
  • Genetic Diversity of Plasmodium Falciparum Candidate Antigen Genes among Field Isolates from Karachi, Pakistan.
    $ 31,700. 2005-2009.
  • Relationship of disease severity to serum cytokine profiles, serological and virological data in patients with dengue fever and dengue hemorrhagic fever.
    Funded by URC. Mar 08-Feb 2010.
  • Molecular characterization of molecular drug resistance markers in P. falciparum isolates from Karachi.
    SEK 60,000 Funded by SASNET, Sweden and the Malaria Research Unit of Karolinska Institutet, Sweden. 2006.
  • Development of a simple bedside applicable tool for diagnosis of severe malaria
    $8,500. 2003-2006.
  • Establishment of in vitro test to detect chloroquine resistance P. falciparum among patients attending AKUH. In vivo drug resistance in P. falciparummalaria.
    US $10,000.1999 – 2001.


Dr M Asim Beg
Dr Erum Khan